Rhumbline Advisers Has $422,000 Position in Rockwell Medical, Inc. (RMTI)
Rhumbline Advisers reduced its position in shares of Rockwell Medical, Inc. (NASDAQ:RMTI) by 2.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,160 shares of the company’s stock after selling 1,108 shares during the period. Rhumbline Advisers owned approximately 0.10% of Rockwell Medical worth $422,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Rockwell Medical by 4.9% during the first quarter. Vanguard Group Inc. now owns 1,990,057 shares of the company’s stock worth $12,458,000 after purchasing an additional 93,589 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Rockwell Medical by 0.5% during the first quarter. Wells Fargo & Company MN now owns 115,738 shares of the company’s stock worth $725,000 after purchasing an additional 550 shares in the last quarter. Balasa Dinverno & Foltz LLC raised its holdings in Rockwell Medical by 5.8% during the second quarter. Balasa Dinverno & Foltz LLC now owns 54,300 shares of the company’s stock worth $431,000 after purchasing an additional 3,000 shares in the last quarter. Teachers Advisors LLC raised its holdings in Rockwell Medical by 5.3% during the fourth quarter. Teachers Advisors LLC now owns 78,948 shares of the company’s stock worth $517,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Rockwell Medical by 9.7% during the first quarter. Geode Capital Management LLC now owns 371,700 shares of the company’s stock worth $2,326,000 after purchasing an additional 32,964 shares in the last quarter. 21.36% of the stock is owned by hedge funds and other institutional investors.
Rockwell Medical, Inc. (RMTI) opened at 7.73 on Friday. The stock’s market capitalization is $399.95 million. The firm has a 50-day moving average of $6.88 and a 200-day moving average of $7.14. Rockwell Medical, Inc. has a one year low of $3.55 and a one year high of $8.98.
Rockwell Medical (NASDAQ:RMTI) last posted its earnings results on Wednesday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). The firm had revenue of $13.24 million for the quarter, compared to analyst estimates of $13.05 million. Rockwell Medical had a negative net margin of 39.68% and a negative return on equity of 42.22%. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.11) earnings per share. On average, equities research analysts forecast that Rockwell Medical, Inc. will post ($0.44) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/rhumbline-advisers-has-422000-position-in-rockwell-medical-inc-rmti/1611641.html.
Several research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. BidaskClub cut shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Ifs Securities assumed coverage on shares of Rockwell Medical in a report on Monday, August 14th. They set a “strong-buy” rating and a $11.00 price target for the company. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $9.33.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Want to see what other hedge funds are holding RMTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rockwell Medical, Inc. (NASDAQ:RMTI).
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.